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Most workers have found that ipratropium bromide and /2-adrenergic agents given by inhalation are equally effective in relieving airways obstruction in patients with chronic bronchitis and have found no additional benefit from simultaneous administration of the drugs (Gutersohn et al, 1975; Hertz and Strietzel, 1975; Petrie and Palmer, 1975; Poppius and Salorinne, 1975) .
Recently, it has been suggested (McGavin et al, 1976; 1977) (McKerrow et al, 1960) taking the best of three readings (Freedman and Prowse, 1966) and the 12 MD (McGavin et al, 1976) . Subjective estimates of disability were recorded on the Borg Scale (Borg, 1962) and from the point marked by the patients on a structured diagram of everyday activities scaled in proportion to their oxygen cost. Changes after active treatments compared with the change after placebo. The results of these significance tests are **P < 0 01, ***P < 0-001.
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We studied the patients on five consecutive days. On the first day we measured 12 MD on two occasions to accustom the patient to the test and to exclude training effects (McGavin et al, 1976) . On each of the other four days the patients received on a double-blind basis one of the four following treatments, according to a Latin square design and administered by identical pressurised aerosols: ( We measured FEV1 and FVC 15 minutes after the first aerosol and then the second aerosol was given. We repeated measurements of FEV1 and FVC one hour after the second inhalation and then remeasured 12 MD. We calculated analyses of variance that used the Latin square design of the trial. This enables unbiased comparisons between treatments to be made. These analyses are briefly summarised in table 2, and the results of significance tests among the treatment means are indicated by asterisks.
We also calculated correlation coefficients for 12 MD with FEV1, FVC, subjective estimate of disability, and perceived exertion on the Borg Scale before treatment with placebo in the 23 subjects.
Results
The results are summarised in table 2. There were no significant differences at the 5% level between the baseline values for FEV1, FVC, and 12 MD before each treatment.
For both FEV1 and FVC the mean increase in measurement after treatment was substantially greater after all active treatments than after placebo. For each comparison with the placebo the t statistic was highly significant (P<0 001).
The results for 12 MD show the same general pattern. The changes in 12 MD after salbutamol alone and in combination with ipratropium were significantly greater than that after placebo (P<0-01). The change in 12 MD after ipratropium, however, was not large enough compared with the change after placebo to be statistically significant at the 5% level. Although treatment with both salbutamol and ipratropium is associated with the largest increase for 12 MD, FEV1 and FVC, it is not significantly larger than after either drug alone (ie P>0-05).
Of the measurements made before treatment with placebo, 12 MD correlated better with FVC (r=0-6764) and FEV1 (r=0 5278). 12 MD correlated best with subjective estimate of disability (r=0-7818) and was negatively correlated with perceived exertion on the Borg Scale (r= -06050).
Discussion
The strong correlation of the 12 MD with the subjective estimate of disability and weaker correlation with FEV1 found in this study confirm other findings (McGavin et al, 1977) and reinforce the belief that in chronic bronchitic patients the 12 MD is a better index of disability than the FEV1.
The changes in FEV1, FVC, and 12 MD after drugs were recorded at a time when the bronchodilator effects of both drugs reached a maximum (Poppius and Salorinne, 1973; Petrie and Palmer, 1975; Storms and Reed, 1975) . The doses used were chosen on the basis of previous work showing maximum bronchodilatation at these doses without side effects. Larger doses of ipratropium prolong the duration of action without a further significant increase in FEV1 (Alliott et al, 1972; Storms and Reed, 1975 Petrie and Palmer (1975) .
Effect of aerosol ipratropium bromide and salbutamol in chronic bronchitis With both treatments containing salbutamol significant increases in 12 MD were recorded, but the increase observed with ipratropium alone was not significant at the 5% level. The absence of a significant increase in 12 MD with ipratropium when the changes in FEV1 and FVC were virtually identical to those observed after salbutamol is not easily explained. Our findings would suggest, however, that if aerosol bronchodilators in conventional dosage are to be administered to improve exercise tolerance in patients with chronic bronchitis then salbutamol is the drug of choice.
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